Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk

Oncology Reports

Volumn 24, Issue 1, 2010, Pages 257-262

  Gao, Weimin ^a   Romkes, Marjorie ^b,d   Zhong, Shilong ^b   Nukui, Tomoko ^b   Persad, Raj A ^e   Smith, Patrick J B ^e   Branch, Robert ^b   Keohavong, Phouthone ^c,d  

^a TEXAS TECH UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bladder cancer; DNA repair; P53 mutations; X ray repair cross complementing group 1; Xeroderma pigmentosum group D

Indexed keywords

PROTEIN P53; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; DNA BINDING PROTEIN; ERCC2 PROTEIN, HUMAN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADULT; AGED; ALLELE; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER PATIENT; CANCER RISK; CODON; CONTROL GROUP; CONTROLLED STUDY; DNA ISOLATION; DNA REPAIR; EXON; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; BLADDER TUMOR; CASE CONTROL STUDY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; PHYSIOLOGY; RISK; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RISK; URINARY BLADDER NEOPLASMS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 77952997901     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000854     Document Type: Article

References (61)

1. Clavel J, Cordier S, Boccon-Gibod L and Hemon D: Tobacco and bladder cancer in males: increased risk for inhalers and smokers of black tobacco. Int J Cancer 44: 605-610, 1989. (Pubitemid 19258731)
2. D'Avanzo B, Negri E, La Vecchia C, et al: Cigarette smoking and bladder cancer. Eur J Cancer 26: 714-718, 1990.
3. Hartge P, Silverman D, Hoover R, et al: Changing cigarette habits and bladder cancer risk: a case-control study. J Natl Cancer Inst 78: 1119-1125, 1987. (Pubitemid 17113643)
4. Silverman DT, Rothman N and Devesa SS: Bladder Cancer. In: Bladder Cancer: biology, diagnosis, and management. Syrigos KN and Skinner DG (eds). Oxford University Press, New York, pp11-55, 1999.
5. Hecht SS: DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res 424: 127-142, 1999.
6. Wei Q, Cheng L, Hong WK and Spitz MR: Reduced DNA repair capacity in lung cancer patients. Cancer Res 56: 4103-4107, 1996. (Pubitemid 26304997)
7. Denissenko MF, Pao A, Tang M and Pfeifer GP: Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274: 430-432, 1996. (Pubitemid 26353359)
8. Friedberg EC, Walker GC and Siede W: DNA repair and mutagenesis. ASM Press, Washington DC, 1995.
9. Vineis P, Talaska G, Malaveille C, et al: DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer 65: 314-316, 1996. (Pubitemid 26059985)
10. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994. (Pubitemid 24289415)
11. Husgafvel-Pursiainen K and Kannio A: Cigarette smoking and p53 mutations in lung cancer and bladder cancer. Environ Health Perspect 104 (Suppl. 3): S553-S556, 1996. (Pubitemid 26196403)
12. Kannio A, Ridanpaa M, Koskinen H, et al: A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking, and occupational exposure to asbestos. Cancer Epidemiol Biomarkers Prev 5: 33-39, 1996. (Pubitemid 26020541)
13. Ryk C, Berggren P, Kumar R, et al: Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int J Cancer 113: 761-768, 2005. (Pubitemid 40101257)
14. Uchida T, Wada C, Ishida H, et al: p53 mutations and prognosis in bladder tumors. J Urol 153: 1097-1104, 1995.
15. Mohrenweiser HW and Jones IM: Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutat Res 400: 15-24, 1998.
16. Wei Q, Cheng L, Amos CI, et al: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 92: 1764-1772, 2000.
17. Benhamou S and Sarasin A: Variability in nucleotide excision repair and cancer risk: a review. Mutat Res 462: 149-158, 2000. (Pubitemid 30190222)
18. Batty DP and Wood RD: Damage recognition in nucleotide excision repair of DNA. Gene 241: 193-204, 2000. (Pubitemid 30009848)
19. Shen MR, Jones IM and Mohrenweiser H: Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58: 604-608, 1998.
20. Wilson DM III and Thompson LH: Life without DNA repair. Proc Natl Acad Sci USA 94: 12754-12757, 1997.
21. Caldecott KW, Aoufouchi S, Johnson P and Shall S: XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro. Nucleic Acids Res 24: 4387-4394, 1996.
22. Cappelli E, Taylor R, Cevasco M, Abbondandolo A, Caldecott K and Frosina G: Involvement of XRCC1 and DNA ligase III gene products in DNA base excision repair. J Biol Chem 272: 23970-23975, 1997. (Pubitemid 27410980)
23. Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE and Lindahl T: Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J 15: 6662-6670, 1996. (Pubitemid 26413798)
24. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J and de Murcia G: XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18: 3563-3571, 1998. (Pubitemid 28240528)
25. Thompson LH, Brookman KW, Jones NJ, Allen SA and Carrano AV: Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange. Mol Cell Biol 10: 6160-6171, 1990.
26. Thompson LH and West MG: XRCC1 keeps DNA from getting stranded. Mutat Res 459: 1-18, 2000.
27. Marintchev A, Robertson A, Dimitriadis EK, Prasad R, Wilson SH and Mullen GP: Domain specific interaction in the XRCC1-DNA polymerase beta complex. Nucleic Acids Res 28: 2049-2059, 2000. (Pubitemid 30255525)
28. Andrew AS, Nelson HH, Kelsey KT, et al: Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis 27: 1030-1037, 2006.
29. Goode EL, Ulrich CM and Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11: 1513-1530, 2002. (Pubitemid 36020002)
30. Lao T, Gu W and Huang Q: A meta-analysis on XRCC1 R399Q and R194W polymorphisms, smoking and bladder cancer risk. Mutagenesis 23: 523-532, 2008.
31. Matullo G, Guarrera S, Sacerdote C, et al: Polymorphisms/ haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. Cancer Epidemiol Biomarkers Prev 14: 2569-2578, 2005. (Pubitemid 41752717)
32. Sanyal S, Festa F, Sakano S, et al: Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 25: 729-734, 2004. (Pubitemid 38618524)
33. Stern MC, Johnson LR, Bell DA and Taylor JA: XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 11: 1004-1011, 2002.
34. Stern MC, Umbach DM, Lunn RM and Taylor JA: DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 11: 939-943, 2002.
35. Stern MC, Umbach DM, van Gils CH, Lunn RM and Taylor JA: DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 10: 125-131, 2001. (Pubitemid 32172431)
36. Wang C, Sun Y and Han R: XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis. Urology 72: 869-872, 2008.
37. Wang F, Chang D, Hu FL, et al: DNA repair gene XPD polymorphisms and cancer risk: a meta-analysis based on 56 case-control studies. Cancer Epidemiol Biomarkers Prev 17: 507-517, 2008. (Pubitemid 351469199)
38. Shen M, Hung RJ, Brennan P, et al: Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy. Cancer Epidemiol Biomarkers Prev 12: 1234-1240, 2003. (Pubitemid 37499450)
39. Covolo L, Placidi D, Gelatti U, et al: Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case-control study. Eur J Epidemiol 23: 355-362, 2008.
40. Buch S, Zhu B, Davis AG, et al: Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog 42: 222-228, 2005. (Pubitemid 40504693)
41. Gao WM, Mady HH, Yu GY, et al: Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types. Lung Cancer 40: 141-150, 2003.
42. Gealy R, Zhang L, Siegfried JM, Luketich JD and Keohavong P: Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev 8: 297-302, 1999. (Pubitemid 29193900)
43. Gao WM, Romkes M, Day RD, et al: Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Carcinogenesis 24: 1671-1676, 2003. (Pubitemid 37304673)
44. Gao WM, Romkes M, Siegfried JM, Luketich JD and Keohavong P: No association between the XPD 312, 751, or XRCC1 399 polymorphisms and K-ras gene mutation in smoking non-small-cell lung cancer. Cancer Epidemiol Biomarkers Prev 13: 673-675, 2004. (Pubitemid 38737908)
45. Gao WM, Romkes M, Siegfried JM, Luketich JD and Keohavong P: Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never-smokers. Mol Carcinog 45: 828-832, 2006. (Pubitemid 44646334)
46. Narter KF, Ergen A, Agachan B, Gormus U, Timirci O and Isbir T: Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). Anticancer Res 29: 1389-1393, 2009.
47. Gangwar R, Ahirwar D, Mandhani A and Mittal RD: Influence of XPD and APE1 DNA repair gene polymorphism on bladder cancer susceptibility in north India. Urology 73: 675-680, 2009.
48. Ryk C, Kumar R, Sanyal S, et al: Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett 241: 142-149, 2006.
49. Sakano S, Matsumoto H, Yamamoto Y, et al: Association between DNA repair gene polymorphisms and p53 alterations in Japanese patients with muscle-invasive bladder cancer. Pathobiology 73: 295-303, 2006. (Pubitemid 44325895)
50. Stern MC, Conway K, Li Y, Mistry K and Taylor JA: DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Mol Carcinog 45: 715-719, 2006. (Pubitemid 44406643)
51. Fujimoto K, Yamada Y, Okajima E, et al: Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52: 1393-1398, 1992.
52. Brockmoller J, Kaiser R, Kerb R, Cascorbi I, Jaeger V and Roots I: Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. Pharmacogenetics 6: 535-545, 1996. (Pubitemid 27032306)
53. Spruck CH III, Rideout WM III, Olumi AF, et al: Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res 53: 1162-1166, 1993.
54. Taylor JA, Li Y, He M, et al: p53 mutations in bladder tumors from arylamine-exposed workers. Cancer Res 56: 294-298, 1996. (Pubitemid 26026357)
55. Berggren P, Steineck G, Adolfsson J, et al: p53 mutations in urinary bladder cancer. Br J Cancer 84: 1505-1511, 2001. (Pubitemid 32579343)
56. Schroeder JC, Conway K, Li Y, Mistry K, Bell DA and Taylor JA: p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Cancer Res 63: 7530-7538, 2003. (Pubitemid 37413499)
57. Ames BN: Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science 221: 1256-1264, 1983.
58. Kalra J, Chaudhary AK and Prasad K: Increased production of oxygen free radicals in cigarette smokers. Int J Exp Pathol 72: 1-7, 1991.
59. Matullo G, Dunning AM, Guarrera S, et al: DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 27: 997-1007, 2006.
60. Feng Z, Hu W, Rom WN, Beland FA and Tang MS: 4-aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis 23: 1721-1727, 2002. (Pubitemid 35214958)
61. Moore LE, Smith AH, Eng C, et al: P53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis 24: 1785-1791, 2003. (Pubitemid 37408142)